HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN US PATIENTS WITH 2L+ RECURRENT OR PROGRESSIVE ENDOMETRIAL CANCER (EC)
Author(s)
Rachel Bhak, MS1, Jing He, PhD1, Neeraj N. Iyer, MS, PhD1, Olayiwola Popoola, PhD1, Audrey Hopkins, PhD1, Murat M. Ikiisik, MD1, Fernanda Musa, MD2;
1Genmab, Princeton, NJ, USA, 2Providence-Swedish Cancer Institute, Seattle, WA, USA
1Genmab, Princeton, NJ, USA, 2Providence-Swedish Cancer Institute, Seattle, WA, USA
OBJECTIVES: Describe HRU and costs among patients treated with ≥2 lines of therapy (LOTs) to understand economic burden in advanced EC.
METHODS: This retrospective observational study used US MarketScan claims data (2018-2024) and included patients with EC treated with ≥2 LOTs. All-cause and EC-specific HRU and costs were evaluated by LOT and stratified by commercial and Medicare payer type.
RESULTS: 646 patients were included; 70.9% and 29.1% were covered by commercial and Medicare plans, respectively. Mean age was 62.3 years, and 2L was initiated in 2019-2021 for 34.8% and in 2022-2024 for 65.2% of patients. Among the commercially insured population, during 2L treatment, 28.2% had an all-cause inpatient admission with a corresponding median length of stay (LOS) of 7.0 days. During 3L and 4L, the proportions with an all-cause inpatient admission were 31.7% (LOS: 5.0) and 24.1% (LOS: 6.0), respectively. For outpatient care, mean (SD) visits per-patient-per-month (PPPM) were 5.4 (3.1), 5.9 (3.0), and 5.4 (2.5) for 2L, 3L, and 4L, respectively. Mean (SD) all-cause total costs (USD 2025) PPPM were $40,615 (45,188) in 2L, $34,533 (29,602) in 3L, and $31,124 (18,018) in 4L. For the Medicare-insured population in 2L, 34.4% had an all-cause inpatient admission with median LOS of 7.0 days. During 3L and 4L, the proportions with an all-cause inpatient admission were 27.8% (LOS: 3.5) and 60.0% (LOS: 4.0), respectively. For outpatient care, mean (SD) visits PPPM were 5.7 (3.0), 6.1 (2.7), and 6.3 (2.8) for 2L, 3L, and 4L, respectively. Mean (SD) all-cause total costs PPPM were $20,588 (15,128) in 2L, $12,377 (10,520) in 3L, and $20,677 (15,728) in 4L. EC-specific metrics show approximately 85% of HRU and costs are related to EC.
CONCLUSIONS: EC patients on ≥2 LOTs incurred substantial HRU and costs, including frequent hospitalizations and outpatient visits, indicating significant clinical and economic burden.
METHODS: This retrospective observational study used US MarketScan claims data (2018-2024) and included patients with EC treated with ≥2 LOTs. All-cause and EC-specific HRU and costs were evaluated by LOT and stratified by commercial and Medicare payer type.
RESULTS: 646 patients were included; 70.9% and 29.1% were covered by commercial and Medicare plans, respectively. Mean age was 62.3 years, and 2L was initiated in 2019-2021 for 34.8% and in 2022-2024 for 65.2% of patients. Among the commercially insured population, during 2L treatment, 28.2% had an all-cause inpatient admission with a corresponding median length of stay (LOS) of 7.0 days. During 3L and 4L, the proportions with an all-cause inpatient admission were 31.7% (LOS: 5.0) and 24.1% (LOS: 6.0), respectively. For outpatient care, mean (SD) visits per-patient-per-month (PPPM) were 5.4 (3.1), 5.9 (3.0), and 5.4 (2.5) for 2L, 3L, and 4L, respectively. Mean (SD) all-cause total costs (USD 2025) PPPM were $40,615 (45,188) in 2L, $34,533 (29,602) in 3L, and $31,124 (18,018) in 4L. For the Medicare-insured population in 2L, 34.4% had an all-cause inpatient admission with median LOS of 7.0 days. During 3L and 4L, the proportions with an all-cause inpatient admission were 27.8% (LOS: 3.5) and 60.0% (LOS: 4.0), respectively. For outpatient care, mean (SD) visits PPPM were 5.7 (3.0), 6.1 (2.7), and 6.3 (2.8) for 2L, 3L, and 4L, respectively. Mean (SD) all-cause total costs PPPM were $20,588 (15,128) in 2L, $12,377 (10,520) in 3L, and $20,677 (15,728) in 4L. EC-specific metrics show approximately 85% of HRU and costs are related to EC.
CONCLUSIONS: EC patients on ≥2 LOTs incurred substantial HRU and costs, including frequent hospitalizations and outpatient visits, indicating significant clinical and economic burden.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE267
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology, STA: Biologics & Biosimilars